Evidence map›Paper›PMID 42592442›Full record

ArticleActa pharmaceutica Sinica. B2026

Preclinical evaluation of a novel tetrazine probe within a pretargeted delivery system for theranostics in HER2-positive tumor-bearing mice models.

Pengcheng Ma, Hui Tan, Qingyu Lin, Yuxia Liu, Hua Shen, Shuhua He, Hongxing Su, Zonghua Luo, Dai Shi, Dengfeng Cheng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Pengcheng MaDepartment of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Hui TanDepartment of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Qingyu LinDepartment of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Yuxia LiuDepartment of Applied Chemistry, Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai 201800, China.
Hua ShenDepartment of Applied Chemistry, Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai 201800, China.
Shuhua HeDepartment of Applied Chemistry, Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai 201800, China.
Hongxing SuDepartment of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Zonghua LuoDepartment of Nuclear Medicine, Shanghai Clinical Research and Trial Center, Shanghai 201210, China.
Dai ShiDepartment of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Dengfeng ChengDepartment of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The approval of radionuclide therapy strategies in nuclear medicine has revolutionized the treatment landscape for patients with advanced malignancies. Due to significant HER2 overexpression in some solid tumors, radionuclide therapy targeting HER2 is a viable strategy. The traditional monoclonal antibody (mAb) direct radiolabelling system may lead to off-target radiation exposure. To address this limitation, we employed the established inverse-electron demand Diels-Alder (IEDDA)-based pretargeting strategy and designed a novel tetrazine probe. First, we identified the optimal targeting molecule (Pertuzumab) and optimal metabolic time (48 h) through micro-positron emission tomography/computed tomography (PET/CT) scans and biodistribution studies of [

Indexed as

[131I]I-Tyr-d-peptide-PEG11-TzBioorthogonal click chemistryHER2Nuclear medicinePretargetingRadionuclide targeting delivery systemRadionuclide therapyTheranostic

Identifiers

PMID42592442
PMCPMC13464068

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.